Covid-19 Research

Short Communication

Cell-to-Cell Communication in Prostate Differentiation and Cancer

Journal of Biomedical Research & Environmental Sciences article abstract with citation details, DOI, publication dates, subject areas, full text links, and references.

View DOI Submit Manuscript

Article Details

Publication record, authors, dates, abstract, and full text access.

Open Access
Article Type Short Communication
Subject Medicine Group
OCLC JBRES Record
Alvin Y Liu*
Issue: Volume5-Issue10
Pages: 1338-1348
Received: 2024-10-01
Accepted: 2024-10-22
Published: 2024-10-22

Abstract

FullText HTML FullText PDF DOI: 10.37871/jbres2021 Crossmark

Certificate of Publication

Certificate of Publication

Copyright

© 2024 Liu AY. Distributed under Creative Commons CC-BY 4.0 Creative CommonsAttribution

How to cite this article

Liu AY. Cell-to-Cell Communication in Prostate Differentiation and Cancer. J Biomed Res Environ Sci. 2024 Oct 22; 5(10): 1338-1348. doi: 10.37871/jbres2021, Article ID: JBRES2021, Available at: https://www.jelsciences.com/articles/jbres2021.pdf

Subject area(s)

OncologyCancer

References

  1. Jain MA, Leslie SW, Sapra A. Prostate cancer screening. Stats Pearl Publishin. Treasure Island, FL. 2024.
  2. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005 Oct 28;310(5748):644-8. doi: 10.1126/science.1117679. PMID: 16254181.
  3. Allemailem KS, Almatroudi A, Alrumaihi F, Makki Almansour N, Aldakheel FM, Rather RA, Afroze D, Rah B. Single nucleotide polymorphisms (SNPs) in prostate cancer: its implications in diagnostics and therapeutics. Am J Transl Res. 2021 Apr 15;13(4):3868-3889. PMID: 34017579; PMCID: PMC8129253.
  4. Stoyanova T, Riedinger M, Lin S, Faltermeier CM, Smith BA, Zhang KX, Going CC, Goldstein AS, Lee JK, Drake JM, Rice MA, Hsu EC, Nowroozizadeh B, Castor B, Orellana SY, Blum SM, Cheng D, Pienta KJ, Reiter RE, Pitteri SJ, Huang J, Witte ON. Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):E6457-E6466. doi: 10.1073/pnas.1614529113. Epub 2016 Sep 30. PMID: 27694579; PMCID: PMC5081658.
  5. Cunha GR. Mesenchymal-epithelial interactions: past, present, and future. Differentiation. 2008 Jul;76(6):578-86. doi: 10.1111/j.1432-0436.2008.00290.x. Epub 2008 Jun 28. PMID: 18557761.
  6. Aboseif S, El-Sakka A, Young P, Cunha G. Mesenchymal reprogramming of adult human epithelial differentiation. Differentiation. 1999 Oct;65(2):113-8. doi: 10.1046/j.1432-0436.1999.6520113.x. PMID: 10550544.
  7. Liu AY, True LD. Characterization of prostate cell types by CD cell surface molecules. Am J Pathol. 2002 Jan;160(1):37-43. doi: 10.1016/S0002-9440(10)64346-5. PMID: 11786396; PMCID: PMC1867111.
  8. Liu AY, Roudier MP, True LD. Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile. Am J Pathol. 2004 Nov;165(5):1543-56. doi: 10.1016/S0002-9440(10)63412-8. PMID: 15509525; PMCID: PMC1618667.
  9. Oudes AJ, Campbell DS, Sorensen CM, Walashek LS, True LD, Liu AY. Transcriptomes of human prostate cells. BMC Genomics. 2006 Apr 25;7:92. doi: 10.1186/1471-2164-7-92. PMID: 16638148; PMCID: PMC1553448.
  10. Pascal LE, Oudes AJ, Petersen TW, Goo YA, Walashek LS, True LD, Liu AY. Molecular and cellular characterization of ABCG2 in the prostate. BMC Urol. 2007 Apr 10;7:6. doi: 10.1186/1471-2490-7-6. PMID: 17425799; PMCID: PMC1853103.
  11. Liu AY, Vêncio RZ, Page LS, Ho ME, Loprieno MA, True LD. Bladder expression of CD cell surface antigens and cell-type-specific transcriptomes. Cell Tissue Res. 2012 Jun;348(3):589-600. doi: 10.1007/s00441-012-1383-y. Epub 2012 Mar 20. PMID: 22427119; PMCID: PMC3367057.
  12. Pascal LE, Vêncio RZ, Goo YA, Page LS, Shadle CP, Liu AY. Temporal expression profiling of the effects of secreted factors from prostate stromal cells on embryonal carcinoma stem cells. Prostate. 2009 Sep 1;69(12):1353-65. doi: 10.1002/pros.20982. PMID: 19455603.
  13. Vêncio EF, Nelson AM, Cavanaugh C, Ware CB, Milller DG, Garcia JC, Vêncio RZ, Loprieno MA, Liu AY. Reprogramming of prostate cancer-associated stromal cells to embryonic stem-like. Prostate. 2012 Sep 15;72(13):1453-63. doi: 10.1002/pros.22497. Epub 2012 Feb 7. PMID: 22314551..
  14. Liu AY. Prostate cancer research: tools, cell types, and molecular targets. Front Oncol. 2024 Mar 26;14:1321694. doi: 10.3389/fonc.2024.1321694. PMID: 38595814; PMCID: PMC11002103.
  15. Liu AY, LaTray L, van Den Engh G. Changes in cell surface molecules associated with in vitro culture of prostatic stromal cells. Prostate. 2000 Sep 1;44(4):303-12. doi: 10.1002/1097-0045(20000901)44:4<303::aid-pros7>3.0.co;2-j. PMID: 10951495.
  16. Kanan AD, Corey E, Vêncio RZN, Ishwar A, Liu AY. Lineage relationship between prostate adenocarcinoma and small cell carcinoma. BMC Cancer. 2019 May 30;19(1):518. doi: 10.1186/s12885-019-5680-7. PMID: 31146720; PMCID: PMC6543672.
  17. Goo YA, Goodlett DR, Pascal LE, Worthington KD, Vessella RL, True LD, Liu AY. Stromal mesenchyme cell genes of the human prostate and bladder. BMC Urol. 2005 Dec 12;5:17. doi: 10.1186/1471-2490-5-17. PMID: 16343351; PMCID: PMC1327674.
  18. True LD, Zhang H, Ye M, Huang CY, Nelson PS, von Haller PD, Tjoelker LW, Kim JS, Qian WJ, Smith RD, Ellis WJ, Liebeskind ES, Liu AY. CD90/THY1 is overexpressed in prostate cancer-associated fibroblasts and could serve as a cancer biomarker. Mod Pathol. 2010 Oct;23(10):1346-56. doi: 10.1038/modpathol.2010.122. Epub 2010 Jun 18. PMID: 20562849; PMCID: PMC2948633.
  19. Pascal LE, Ai J, Vêncio RZ, Vêncio EF, Zhou Y, Page LS, True LD, Wang Z, Liu AY. Differential Inductive Signaling of CD90 Prostate Cancer-Associated Fibroblasts Compared to Normal Tissue Stromal Mesenchyme Cells. Cancer Microenviron. 2011 Jan 7;4(1):51-9. doi: 10.1007/s12307-010-0061-4. PMID: 21505567; PMCID: PMC3047627..
  20. Liu AY. The opposing action of stromal cell proenkephalin and stem cell transcription factors in prostate cancer differentiation. BMC Cancer. 2021 Dec 15;21(1):1335. doi: 10.1186/s12885-021-09090-y. PMID: 34911496; PMCID: PMC8675470.
  21. Rosen H, Krichevsky A, Polakiewicz RD, Benzakine S, Bar-Shavit Z. Developmental regulation of proenkephalin gene expression in osteoblasts. Mol Endocrinol. 1995 Nov;9(11):1621-31. doi: 10.1210/mend.9.11.8584038. PMID: 8584038.
  22. Varghese R, Wong CK, Deol H, Wagner GF, DiMattia GE. Comparative analysis of mammalian stanniocalcin genes. Endocrinology. 1998 Nov;139(11):4714-25. doi: 10.1210/endo.139.11.6313. PMID: 9794484.
  23. Pascal LE, Goo YA, Vêncio RZ, Page LS, Chambers AA, Liebeskind ES, Takayama TK, True LD, Liu AY. Gene expression down-regulation in CD90+ prostate tumor-associated stromal cells involves potential organ-specific genes. BMC Cancer. 2009 Sep 8;9:317. doi: 10.1186/1471-2407-9-317. PMID: 19737398; PMCID: PMC2745432.
  24. Pascal LE, Vêncio RZ, Page LS, Liebeskind ES, Shadle CP, Troisch P, Marzolf B, True LD, Hood LE, Liu AY. Gene expression relationship between prostate cancer cells of Gleason 3, 4 and normal epithelial cells as revealed by cell type-specific transcriptomes. BMC Cancer. 2009 Dec 18;9:452. doi: 10.1186/1471-2407-9-452. PMID: 20021671; PMCID: PMC2809079.
  25. Vêncio EF, Pascal LE, Page LS, Denyer G, Wang AJ, Ruohola-Baker H, Zhang S, Wang K, Galas DJ, Liu AY. Embryonal carcinoma cell induction of miRNA and mRNA changes in co-cultured prostate stromal fibromuscular cells. J Cell Physiol. 2011 Jun;226(6):1479-88. doi: 10.1002/jcp.22464. PMID: 20945389; PMCID: PMC3968429.
  26. Goo YA, Liu AY, Ryu S, Shaffer SA, Malmström L, Page L, Nguyen LT, Doneanu CE, Goodlett DR. Identification of secreted glycoproteins of human prostate and bladder stromal cells by comparative quantitative proteomics. Prostate. 2009 Jan 1;69(1):49-61. doi: 10.1002/pros.20853. PMID: 18792917; PMCID: PMC4281891.
  27. Krichevsky AM, Gabriely G. miR-21: a small multi-faceted RNA. J Cell Mol Med. 2009 Jan;13(1):39-53. doi: 10.1111/j.1582-4934.2008.00556.x. PMID: 19175699; PMCID: PMC3823035.
  28. van der Voort R, Taher TE, Derksen PW, Spaargaren M, van der Neut R, Pals ST. The hepatocyte growth factor/Met pathway in development, tumorigenesis, and B-cell differentiation. Adv Cancer Res. 2000;79:39-90. doi: 10.1016/s0065-230x(00)79002-6. PMID: 10818677.
  29. Baker SG, Soto AM, Sonnenschein C, Cappuccio A, Potter JD, Kramer BS. Plausibility of stromal initiation of epithelial cancers without a mutation in the epithelium: a computer simulation of morphostats. BMC Cancer. 2009 Mar 23;9:89. doi: 10.1186/1471-2407-9-89. PMID: 19309499; PMCID: PMC2663766.
  30. Pascal LE, Vêncio RZ, Vessella RL, Ware CB, Vêncio EF, Denyer G, Liu AY. Lineage relationship of prostate cancer cell types based on gene expression. BMC Med Genomics. 2011 May 23;4:46. doi: 10.1186/1755-8794-4-46. PMID: 21605402; PMCID: PMC3113924.
  31. Borges GT, Vêncio EF, Quek SI, Chen A, Salvanha DM, Vêncio RZ, Nguyen HM, Vessella RL, Cavanaugh C, Ware CB, Troisch P, Liu AY. Conversion of Prostate Adenocarcinoma to Small Cell Carcinoma-Like by Reprogramming. J Cell Physiol. 2016 Sep;231(9):2040-7. doi: 10.1002/jcp.25313. Epub 2016 Feb 4. PMID: 26773436.
  32. Saar M, Zhao H, Nolley R, Young SR, Coleman I, Nelson PS, Vessella RL, Peehl DM. Spheroid culture of LuCaP 147 as an authentic preclinical model of prostate cancer subtype with SPOP mutation and hypermutator phenotype. Cancer Lett. 2014 Sep 1;351(2):272-80. doi: 10.1016/j.canlet.2014.06.014. Epub 2014 Jul 3. PMID: 24998678; PMCID: PMC4112013.
  33. de Thé H. Differentiation therapy revisited. Nat Rev Cancer. 2018 Feb;18(2):117-127. doi: 10.1038/nrc.2017.103. Epub 2017 Dec 1. PMID: 29192213.
  34. Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Du VY, Schlessinger J, Goldberg SB, Chiang A, Sanmamed MF, Melero I, Agorreta J, Montuenga LM, Lifton R, Ferrone S, Kavathas P, Rimm DL, Kaech SM, Schalper K, Herbst RS, Politi K. Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discov. 2017 Dec;7(12):1420-1435. doi: 10.1158/2159-8290.CD-17-0593. Epub 2017 Oct 12. PMID: 29025772; PMCID: PMC5718941.
  35. Fessart D, Domblides C, Avril T, Eriksson LA, Begueret H, Pineau R, Malrieux C, Dugot-Senant N, Lucchesi C, Chevet E, Delom F. Secretion of protein disulphide isomerase AGR2 confers tumorigenic properties. Elife. 2016 May 30;5:e13887. doi: 10.7554/eLife.13887. PMID: 27240165; PMCID: PMC4940162.
  36. Ho ME, Quek SI, True LD, Seiler R, Fleischmann A, Bagryanova L, Kim SR, Chia D, Goodglick L, Shimizu Y, Rosser CJ, Gao Y, Liu AY. Bladder cancer cells secrete while normal bladder cells express but do not secrete AGR2. Oncotarget. 2016 Mar 29;7(13):15747-56. doi: 10.18632/oncotarget.7400. PMID: 26894971; PMCID: PMC4941274.
  37. Ho ME, Quek SI, True LD, Morrissey C, Corey E, Vessella RL, Dumpit R, Nelson PS, Maresh EL, Mah V, Alavi M, Kim SR, Bagryanova L, Horvath S, Chia D, Goodglick L, Liu AY. Prostate cancer cell phenotypes based on AGR2 and CD10 expression. Mod Pathol. 2013 Jun;26(6):849-59. doi: 10.1038/modpathol.2012.238. Epub 2013 Jan 25. PMID: 23348903; PMCID: PMC3638070.
  38. Maresh EL, Mah V, Alavi M, Horvath S, Bagryanova L, Liebeskind ES, Knutzen LA, Zhou Y, Chia D, Liu AY, Goodglick L. Differential expression of anterior gradient gene AGR2 in prostate cancer. BMC Cancer. 2010 Dec 13;10:680. doi: 10.1186/1471-2407-10-680. PMID: 21144054; PMCID: PMC3009682.
  39. Wambach M, Montani M, Runz J, Stephan C, Jung K, Moch H, Eberli D, Bernhardt M, Hommerding O, Kreft T, Cronauer MV, Kremer A, Mayr T, Hauser S, Kristiansen G. Clinical implications of AGR2 in primary prostate cancer: Results from a large-scale study. APMIS. 2024 Apr;132(4):256-266. doi: 10.1111/apm.13382. Epub 2024 Jan 30. PMID: 38288749.
  40. Dall'Era MA, True LD, Siegel AF, Porter MP, Sherertz TM, Liu AY. Differential expression of CD10 in prostate cancer and its clinical implication. BMC Urol. 2007 Mar 2;7:3. doi: 10.1186/1471-2490-7-3. PMID: 17335564; PMCID: PMC1829163.
  41. Vitello EA, Quek SI, Kincaid H, Fuchs T, Crichton DJ, Troisch P, Liu AY. Cancer-secreted AGR2 induces programmed cell death in normal cells. Oncotarget. 2016 Aug 2;7(31):49425-49434. doi: 10.18632/oncotarget.9921. PMID: 27283903; PMCID: PMC5226518.
  42. Wayner EA, Quek SI, Ahmad R, Ho ME, Loprieno MA, Zhou Y, Ellis WJ, True LD, Liu AY. Development of an ELISA to detect the secreted prostate cancer biomarker AGR2 in voided urine. Prostate. 2012 Jun 15;72(9):1023-34. doi: 10.1002/pros.21508. Epub 2011 Nov 9. PMID: 22072305.
  43. Casero RA, Pegg AE. Spermidine/spermine N1-acetyltransferase - The turning point in polyamine metabolism. FASEB J. 1993;7:653-661. doi: 10.1096/fasebj.7.8.8500690.
  44. Negi H, Merugu SB, Mangukiya HB, Li Z, Zhou B, Sehar Q, Kamle S, Yunus FU, Mashausi DS, Wu Z, Li D. Anterior Gradient-2 monoclonal antibody inhibits lung cancer growth and metastasis by upregulating p53 pathway and without exerting any toxicological effects: A preclinical study. Cancer Lett. 2019 May 1;449:125-134. doi: 10.1016/j.canlet.2019.01.025. Epub 2019 Jan 25. PMID: 30685412.
  45. Barron DA, Rowley DR. The reactive stroma microenvironment and prostate cancer progression. Endocr Relat Cancer. 2012 Oct 30;19(6):R187-204. doi: 10.1530/ERC-12-0085. PMID: 22930558; PMCID: PMC3716392.
  46. Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, Weinstein AS, Friedl V, Zhang C, Witte ON, Lloyd P, Gleave M, Evans CP, Youngren J, Beer TM, Rettig M, Wong CK, True L, Foye A, Playdle D, Ryan CJ, Lara P, Chi KN, Uzunangelov V, Sokolov A, Newton Y, Beltran H, Demichelis F, Rubin MA, Stuart JM, Small EJ. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. J Clin Oncol. 2018 Aug 20;36(24):2492-2503. doi: 10.1200/JCO.2017.77.6880. Epub 2018 Jul 9. PMID: 29985747; PMCID: PMC6366813.
  47. Liu AY, True LD, LaTray L, Nelson PS, Ellis WJ, Vessella RL, Lange PH, Hood L, van den Engh G. Cell-cell interaction in prostate gene regulation and cytodifferentiation. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10705-10. doi: 10.1073/pnas.94.20.10705. PMID: 9380699; PMCID: PMC23453.
  48. Liu AY, Kanan AD, Radon TP, Shah S, Weeks ME, Foster JM, Sosabowski JK, Dumartin L, Crnogorac-Jurcevic T. AGR2, a unique tumor-associated antigen, is a promising candidate for antibody targeting. Oncotarget. 2019 Jul 2;10(42):4276-4289. doi: 10.18632/oncotarget.26945. PMID: 31303962; PMCID: PMC6611513.
  49. Nguyen HM, Vessella RL, Morrissey C, Brown LG, Coleman IM, Higano CS, Mostaghel EA, Zhang X, True LD, Lam HM, Roudier M, Lange PH, Nelson PS, Corey E. LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics. Prostate. 2017 May;77(6):654-671. doi: 10.1002/pros.23313. Epub 2017 Feb 3. PMID: 28156002; PMCID: PMC5354949.
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership